Eghbali Kamyar, Shayegan Mohammad Reza, Kianoush Sina
Department of Urology, Mashhad Branch, Islamic Azad University, Mashhad, Iran;
Can Urol Assoc J. 2013 May-Jun;7(5-6):E317-21. doi: 10.5489/cuaj.11262. Epub 2013 May 13.
According to previous studies, aging, gender, bladder volume and pathological states, such as bladder outflow obstruction, affect bladder wall thickness (BWT). The aim of this study was to evaluate the correlation between BWT and the International Prostatic Symptom Score (IPSS) in patients with benign prostatic hyperplasia (BPH) before and after tamsulosin treatment.
In this study, 60 BPH patients were included. After obtaining informed consent, data were gathered using questionnaires to determine IPSS. After that, prostate-specific antigen was measured and a clinical examination, including a digital rectal examination, was performed for all patients. BWT was determined by transabdominal ultrasound. Finally, all patients were treated with tamsulosin (0.4 mg/day) for 2 months. After completing treatment, the IPSS and BWT were measured again and compared with the initial findings.
In total, 44 patients completed treatment. Patients aged 61.7 ± 9.2 years old. The mean ± standard deviation of IPSS and BWT were 14.6 ± 5.0 and 5.36 ± 1.28 mm before treatment, while they significantly (p < 0.0001) decreased to 8.2 ± 4.7 and 4.69 ± 1.23 mm, respectively, after treatment. Chi-square test showed that the decrease in BWT was significantly correlated with the improvement in IPSS (p = 0.002; r = 0.449).
After treatment with tamsulosin, patients experienced a reduction in their BWT which was significantly correlated with improvement in their IPSS. We conclude that transabdominal evaluation of BWT could be included in the follow-up assessment in BPH.
根据以往研究，衰老、性别、膀胱容量以及诸如膀胱流出道梗阻等病理状态会影响膀胱壁厚度（BWT）。本研究的目的是评估坦索罗辛治疗前后良性前列腺增生（BPH）患者的BWT与国际前列腺症状评分（IPSS）之间的相关性。
本研究纳入了60例BPH患者。在获得知情同意后，通过问卷收集数据以确定IPSS。之后，测量所有患者的前列腺特异性抗原，并进行包括直肠指检在内的临床检查。通过经腹超声测定BWT。最后，所有患者接受坦索罗辛（0.4mg/天）治疗2个月。完成治疗后，再次测量IPSS和BWT，并与初始结果进行比较。
共有44例患者完成治疗。患者年龄为61.7±9.2岁。治疗前IPSS和BWT的平均值±标准差分别为14.6±5.0和5.36±1.28mm，而治疗后它们分别显著（p<0.0001）降至8.2±4.7和4.69±1.23mm。卡方检验表明，BWT的降低与IPSS的改善显著相关（p = 0.002；r = 0.449）。
坦索罗辛治疗后，患者的BWT降低，且与IPSS的改善显著相关。我们得出结论，经腹评估BWT可纳入BPH的随访评估中。
